PFWA
ENTA icon

Paces Ferry Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Paces Ferry Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5
Closed – – 431
2020
Q3 		$0 Buy
+5
New +$242 ﹤0.01% 1149

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paces Ferry Wealth Advisors's ENTA Position: Q4 2020 in Review

Paces Ferry Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 5 shares.

Paces Ferry Wealth Advisors first reported a position in ENTA in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Paces Ferry Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Paces Ferry Wealth Advisors sold 5 Enanta Pharmaceuticals shares in Q4 2020.
  • Paces Ferry Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Paces Ferry Wealth Advisors's Enanta Pharmaceuticals position peaked at $0 in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Paces Ferry Wealth Advisors's 13F filing for Q4 2020, filed 5 Mar 2021.